GoldenGolden
Advanced Search
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a Pasadena, California-based biotechnology and pharmaceuticals company.

Overview

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded in 1989 by R. Bruce Stewart and is headquartered in Pasadena, CA. Specifically, Arrowhead’s therapies utilize gene silencing through triggering the RNA interference mechanism. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

Targeted RNAi Molecule (TRiM) Platform

Arrowhead Pharmaceuticals’ Targeted RNAi Molecule, or TRiM, platform utilizes ligand-mediated delivery and enables tissue-specific targeting in order to develop targeted drug therapies. The TRiM platform currently focuses on tissues within the liver. However, Arrowhead is working to expand the platform’s applications to include tissues in the lungs and tumors.

Timeline

June 21, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics enters into a research and development collaboration.

Funding rounds

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing

Mark Terry

Web

February 27, 2020

Pipeline - Arrowhead Pharmaceuticals, Inc.

Web

Science - Arrowhead Pharmaceuticals, Inc.

Web

The Story Of Arrowhead Pharmaceuticals' Adversity Odyssey

Rob Wright

Web

April 1, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 10, 2021
FierceBiotech
OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals' $75 million series B round. The funding will take the San Diego-based biotech's growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday.
Nick Paul
July 7, 2021
FierceBiotech
Arrowhead Pharmaceuticals has shared early clinical data on its RNAi treatment for clear cell renal cell carcinoma. The readout provides preliminary evidence that ARO-HIF2 lowers levels of its target protein, encouraging Arrowhead to continue its pursuit of Merck's near-approval rival therapy.
Annalee Armstrong
July 2, 2021
FierceBiotech
Arrowhead Pharmaceuticals is pausing a phase 1/2 study for an RNAi therapeutic after rats in a preclinical study showed unexpected lung inflammation. The Pasadena, California-based biopharmaceutical company is developing ARO-ENaC to treat patients with cystic fibrosis. The therapy aims to reduce production in the lungs' airways of a protein associated with airway dehydration and reducing the transport of mucus in patients with the disease.
June 25, 2021
BioSpace
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress - read this article along with other careers information, tips and advice on BioSpace
DelveInsight Business Research, LLP
June 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.